A Human Bone Morphogenetic Protein Antagonist is Down-regulated in Renal Cancer

Overview

Journal Mol Biol Cell

Specialties Cell Biology
Molecular Biology

Date 2007 Nov 23

PMID 18032587

Citations 40

Authors

Kimberly Rose Blish

Wei Wang

Mark C Willingham

Wei Du

Charles E Birse

Surekha R Krishnan

Julie C Brown

Gregory A Hawkins

A Julian Garvin

Ralph B DAgostino Jr

Frank M Torti

Suzy V Torti

Affiliations

Soon will be listed here.

Abstract

We analyzed expression of candidate genes encoding cell surface or secreted proteins in normal kidney and kidney cancer. This screen identified a bone morphogenetic protein (BMP) antagonist, SOSTDC1 (sclerostin domain-containing-1) as down-regulated in kidney tumors. To confirm screening results, we probed cDNA dot blots with SOSTDC1. The SOSTDC1 message was decreased in 20/20 kidney tumors compared with normal kidney tissue. Immunohistochemistry confirmed significant decrease of SOSTDC1 protein in clear cell renal carcinomas relative to normal proximal renal tubule cells (p < 0.001). Expression of SOSTDC1 was not decreased in papillary and chromophobe kidney tumors. SOSTDC1 was abundantly expressed in podocytes, distal tubules, and transitional epithelia of the normal kidney. Transfection experiments demonstrated that SOSTDC1 is secreted and binds to neighboring cells and/or the extracellular matrix. SOSTDC1 suppresses both BMP-7-induced phosphorylation of R-Smads-1, -5, and -8 and Wnt-3a signaling. Restoration of SOSTDC1 in renal clear carcinoma cells profoundly suppresses proliferation. Collectively, these results demonstrate that SOSTDC1 is expressed in the human kidney and decreased in renal clear cell carcinoma. Because SOSTDC1 suppresses proliferation of renal carcinoma cells, restoration of SOSTDC1 signaling may represent a novel target in treatment of renal clear cell carcinoma.

Citing Articles

Exploration and Identification of Vitamin D and Related Genes as Potential Biomarkers for Colorectal Tumors.

Wang L, Xu R, Wang M, Wang M, Su S, Nian Y Onco Targets Ther. 2025; 18:129-145.

PMID: 39872437 PMC: 11769849. DOI: 10.2147/OTT.S495066.

Histopathologic Analysis of Human Kidney Spatial Transcriptomics Data: Toward Precision Pathology.

Isnard P, Li D, Xuanyuan Q, Wu H, Humphreys B Am J Pathol. 2024; 195(1):69-88.

PMID: 39097165 PMC: 11686452. DOI: 10.1016/j.ajpath.2024.06.011.

Comprehensive proteogenomic characterization of rare kidney tumors.

Li G, Chen L, Hsiao Y, Mannan R, Zhang Y, Luo J Cell Rep Med. 2024; 5(5):101547.

PMID: 38703764 PMC: 11148773. DOI: 10.1016/j.xcrm.2024.101547.

gBLUP-GWAS identifies candidate genes, signaling pathways, and putative functional polymorphisms for age at puberty in gilts.

Wijesena H, Nonneman D, Snelling W, Rohrer G, Keel B, Lents C J Anim Sci. 2023; 101.

PMID: 36848325 PMC: 10016198. DOI: 10.1093/jas/skad063.

Role of Sostdc1 in skeletal biology and cancer.

Tong X, Zhu C, Liu L, Huang M, Xu J, Chen X Front Physiol. 2022; 13:1029646.

PMID: 36338475 PMC: 9633957. DOI: 10.3389/fphys.2022.1029646.

References

Fukuda N, Saitoh M, Kobayashi N, Miyazono K . Execution of BMP-4-induced apoptosis by p53-dependent ER dysfunction in myeloma and B-cell hybridoma cells. Oncogene. 2006; 25(25):3509-17. DOI: 10.1038/sj.onc.1209393. View

Miyazono K, Ten Dijke P, Heldin C . TGF-beta signaling by Smad proteins. Adv Immunol. 2000; 75:115-57. DOI: 10.1016/s0065-2776(00)75003-6. View

Major M, Camp N, Berndt J, Yi X, Goldenberg S, Hubbert C . Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. Science. 2007; 316(5827):1043-6. DOI: 10.1126/science/1141515. View

Laurikkala J, Kassai Y, Pakkasjarvi L, Thesleff I, Itoh N . Identification of a secreted BMP antagonist, ectodin, integrating BMP, FGF, and SHH signals from the tooth enamel knot. Dev Biol. 2003; 264(1):91-105. DOI: 10.1016/j.ydbio.2003.08.011. View

Alberici P, Jagmohan-Changur S, de Pater E, van der Valk M, Smits R, Hohenstein P . Smad4 haploinsufficiency in mouse models for intestinal cancer. Oncogene. 2005; 25(13):1841-51. DOI: 10.1038/sj.onc.1209226. View

Gumz M, Zou H, Kreinest P, Childs A, Belmonte L, LeGrand S . Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res. 2007; 13(16):4740-9. DOI: 10.1158/1078-0432.CCR-07-0143. View

He X, Zhang J, Tong W, Tawfik O, Ross J, Scoville D . BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. Nat Genet. 2004; 36(10):1117-21. DOI: 10.1038/ng1430. View

Lehr H, Mankoff D, Corwin D, Santeusanio G, Gown A . Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem. 1997; 45(11):1559-65. DOI: 10.1177/002215549704501112. View

Franzen A , Heldin N . BMP-7-induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21(CIP1) and p27(KIP1). Biochem Biophys Res Commun. 2001; 285(3):773-81. DOI: 10.1006/bbrc.2001.5212. View

10.

Moustakas A, Souchelnytskyi S, Heldin C . Smad regulation in TGF-beta signal transduction. J Cell Sci. 2002; 114(Pt 24):4359-69. DOI: 10.1242/jcs.114.24.4359. View

11.

Urist M . Bone: formation by autoinduction. Science. 1965; 150(3698):893-9. DOI: 10.1126/science.150.3698.893. View

12.

Yamashita H, Ten Dijke P, Huylebroeck D, Sampath T, Andries M, Smith J . Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects. J Cell Biol. 1995; 130(1):217-26. PMC: 2120513. DOI: 10.1083/jcb.130.1.217. View

13.

Miyazaki H, Watabe T, Kitamura T, Miyazono K . BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells. Oncogene. 2004; 23(58):9326-35. DOI: 10.1038/sj.onc.1208127. View

14.

Ghosh-Choudhury N, Woodruff K, Qi W, Celeste A, Abboud S, Ghosh Choudhury G . Bone morphogenetic protein-2 blocks MDA MB 231 human breast cancer cell proliferation by inhibiting cyclin-dependent kinase-mediated retinoblastoma protein phosphorylation. Biochem Biophys Res Commun. 2000; 272(3):705-11. DOI: 10.1006/bbrc.2000.2844. View

15.

Pouliot F, Labrie C . Role of Smad1 and Smad4 proteins in the induction of p21WAF1,Cip1 during bone morphogenetic protein-induced growth arrest in human breast cancer cells. J Endocrinol. 2002; 172(1):187-98. DOI: 10.1677/joe.0.1720187. View

16.

Itasaki N, Jones C, Mercurio S, Rowe A, Domingos P, Smith J . Wise, a context-dependent activator and inhibitor of Wnt signalling. Development. 2003; 130(18):4295-305. DOI: 10.1242/dev.00674. View

17.

Sneddon J, Zhen H, Montgomery K, van de Rijn M, Tward A, West R . Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proc Natl Acad Sci U S A. 2006; 103(40):14842-7. PMC: 1578503. DOI: 10.1073/pnas.0606857103. View

18.

Kawabata M, Imamura T, Miyazono K . Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev. 1998; 9(1):49-61. DOI: 10.1016/s1359-6101(97)00036-1. View

19.

Yanagita M . Modulator of bone morphogenetic protein activity in the progression of kidney diseases. Kidney Int. 2006; 70(6):989-93. DOI: 10.1038/sj.ki.5001731. View

20.

Chen D, Zhao M, Mundy G . Bone morphogenetic proteins. Growth Factors. 2004; 22(4):233-41. DOI: 10.1080/08977190412331279890. View